Welcome to our dedicated page for Erasca SEC filings (Ticker: ERAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Erasca, Inc. (NASDAQ: ERAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage precision oncology issuer. Erasca files current reports on Form 8-K and other documents with the U.S. Securities and Exchange Commission (SEC) that describe financial results, corporate actions, and governance matters.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results for periods ended June 30 and September 30, 2025, where Erasca reported research and development expenses, general and administrative expenses, and net loss figures, along with commentary on its cash, cash equivalents, and marketable securities. Another Form 8-K details the results of the company’s annual meeting of stockholders, including the election of Class I directors and ratification of its independent registered public accounting firm.
For investors analyzing ERAS, these filings complement Erasca’s press releases about its RAS-targeting franchise, including ERAS-0015 and ERAS-4001. While the scientific and clinical details are often highlighted in news announcements, SEC filings provide the formal financial and corporate context, as well as risk factor discussions in periodic reports such as the Form 10-K that the company cites in its cautionary notes.
On Stock Titan, users can review Erasca’s SEC filings as they are made available through EDGAR and use AI-powered summaries to understand key points from lengthy documents, including earnings-related 8-Ks and proxy-related disclosures. This helps readers connect the company’s financial condition and governance decisions with its ongoing efforts to develop therapies for RAS/MAPK pathway-driven cancers.
On June 26 2025, Director James Arthur Bristol submitted a Form 4 reporting an equity award from Erasca, Inc. (ERAS). The filing shows that on June 24 2025 he received 120,000 stock options with an exercise price of $1.45 per share. All of the options vest simultaneously on June 24 2026, provided he remains in continuous service, and they expire on June 23 2035. No open-market purchases or sales of common stock were disclosed, leaving Bristol’s post-transaction direct derivative holdings at 120,000 options.
The transaction constitutes an incentive grant only; it does not alter the current share float, generate cash proceeds, or affect near-term earnings. Nevertheless, the award ties the director’s future value creation to long-term share-price performance.
On 06/24/2025, Erasca, Inc. (ERAS) director Alexander W. Casdin was granted 120,000 stock options to purchase common shares at an exercise price of $1.45. The award was disclosed in a Form 4 filed on 06/26/2025 and is classified as an acquisition rather than an open-market buy.
The options vest 100% on 06/24/2026, contingent on continued board service, and will expire on 06/23/2035. Casdin now holds 120,000 derivative securities, all directly owned. Because no underlying shares were bought or sold and the grant carries no immediate cash outlay, the filing reflects routine director compensation designed to align long-term incentives rather than a directional view on near-term share price.